The Maharashtra FDA has permanently revoked the manufacturing license of InduCare Pharma Pvt. Ltd. in Pune after discovering insects, larvae, and fungal growth in several Ayurvedic products.

Key Takeaways

  • InduCare Pharma Pvt. Ltd. (Pune) loses manufacturing license permanently.
  • Six Ayurvedic medicines failed quality tests due to contamination.
  • Insects, larvae, and fungal growth detected in product samples.
  • Severe violations of Good Manufacturing Practice (GMP) and Drugs and Cosmetics Act.

In a decisive crackdown on substandard pharmaceutical manufacturing, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic manufacturing license of Pune-based InduCare Pharma Pvt. Ltd. The action follows rigorous inspections that revealed alarming sanitary violations and contaminated medicinal products.

Disturbing Findings in Drug Samples

The FDA's investigation uncovered that several medicines were 'Not of Standard Quality' (NSQ). Specifically, samples of Sinhanad Guggul and Punarnavadi Mandur showed significant fungal growth, failing the mandatory Microbial Limit Test. Even more distressing, samples of Hingvastak Churna and Triphala Churna were found to contain insects, larvae, and other foreign impurities, posing a direct threat to consumer health.

Why This Matters

BozokMedia analysis shows that such lapses in the Ayurvedic sector undermine public trust in traditional medicine. When manufacturing facilities fail to maintain basic hygiene and omit essential ingredients specified in approved formulas, it transitions from mere negligence to a significant public health hazard. This enforcement action serves as a critical deterrent for other manufacturers operating under lax standards.

"Providing citizens with safe, quality, and effective medicines is the top responsibility of the Food and Drug Administration," stated Tukaram Mundhe, Commissioner, FDA Maharashtra.

Beyond contamination, the inspection revealed systemic failures: incomplete Batch Manufacturing Records, inadequate laboratory facilities, damaged equipment, and a complete lack of pest-control documentation. The company also failed to provide necessary sales and distribution records, making it difficult to trace affected batches.

Historical Background

The manufacturing of drugs in India is strictly governed by the Drugs and Cosmetics Act, 1940 and the Rules, 1945. These regulations mandate strict adherence to Good Manufacturing Practices (GMP) to ensure that every dose produced is safe, pure, and effective. The recent enforcement campaign by the Maharashtra FDA is part of a broader state-wide initiative to bolster food and drug safety.

Did You Know?: Good Manufacturing Practice (GMP) is a system designed to ensure that products are consistently produced and controlled according to quality standards.

Frequently Asked Questions

1. What were the specific defects found in the medicines?
The medicines contained fungal growth, insects, larvae, and exceeded prescribed microbial limits.

2. Why was the license cancelled permanently instead of a temporary suspension?
The permanent cancellation was due to widespread GMP violations, incomplete records, and the company's failure to provide a satisfactory explanation during the hearing.